Trevigen Cell Assays (TCA), a division of Trevigen, Inc., was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the medical research market. TCA specializes in designing and conducting assays for lead compounds and genotoxic screening based on DNA damage and repair as well as cancer cell behavior.
CometAssay® - Rapid analysis of DNA fragmentation associated with DNA damage.
Detect and quantitate DNA damage
Follow DNA repair
PARP Assay - Measurement of the biotinylatedpoly(ADP-ribose) incorporation
onto histone proteins
Assay inhibitors and activators of PARP activity
Determination of IC50 values for PARP inhibitors
PARG Assay - Measurement of the loss of biotinylated PAR from histones.
Identify inhibitors and activators of PARG activity
Determination of IC50 values for PARG inhibitors
Pharmacodynamic PARP AssayII - Measurement of net PAR levels in cellular extracts and tumor lysates.
Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts
Monitoring the efficacy of PARP inhibitors on PAR formation in vivo
Facilitating development of PARP and PARG targeted therapeutics
Cell Invasion Assay - Analysis of responses to chemokines, toxins, drugs and other analytes of interest. Screening for compounds that influence cellular invasion through:
Tumor cell metastasis
Tankyrase 1 Assay - Identification of Tankyrase 1 (PARP5A) inhibitors. Screening for compounds that inhibit Tankyrase 1 (PARP5A) and identification of IC50 values.
Trevigen has not received any reviews.
Trevigen has not received any endorsements.